@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_head { this: np:hasAssertion dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_assertion; np:hasProvenance dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_provenance; np:hasPublicationInfo dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_publicationInfo; a np:Nanopublication . dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_assertion a np:Assertion . dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_provenance a np:Provenance . dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_publicationInfo a np:PublicationInfo . } dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_assertion { miriam-gene:1728 a ncit:C16612 . lld:C0001418 a ncit:C7057 . dgn-gda:DGNc7529bab2cf4ea21ab3623b02edab8b6 sio:SIO_000628 miriam-gene:1728, lld:C0001418; a sio:SIO_001121 . } dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_provenance { dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_assertion dcterms:description "[The expression of intrinsic resistance to cisplatin in two lung cancer cell lines, one derived from a small cell carcinoma (SW1271) and the other from an adenocarcinoma (A549), relative to a drug-sensitive small cell line SW900, was characterized by: (i) expression of cross-resistance to mitomycin C and cadmium chloride, but increased sensitivity to adriamycin and etoposide; (ii) significantly decreased cisplatin uptake; (iii) elevated levels of glutathione which could be reduced by buthionine L-sulfoximine resulting in significant sensitization of the cells to cisplatin; (iv) a lack of consistent modification of metallothionein content and expression of levels of glutathione S-transferase, glutathione reductase and glutathione peroxidase or of activities of DT-diaphorase or catalase; (v) significantly reduced total DNA-platination levels immediately following a 1 h cisplatin treatment with 10 micrograms/ml (33.3 microM); (vi) increased removal of Pt-GG and Pt-AG adducts by the A549 cells, consistent with increased repair capacity, but a lack of removal of these major adducts by the SW1271 cells indicative of tolerance of this drug-induced DNA damage.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:8400352; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP927151.RAsTi-8qFr1eWk91PDFgHMb7b6CEl-uFJlS4M8qAHvsWw130_publicationInfo { this: dcterms:created "2014-10-02T12:41:28+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }